About
5
Publications
863
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
39
Citations
Introduction
I hold a Pharmacy Degree from Algiers University and a PhD in Management from Paris-Est University. I am currently a lecturer at Sorbonne-Paris-Cité and Paris Dauphine University and a member of the Centre for Research in Economics of Paris-Nord (CEPN). I was a visiting researcher at Brunel Business School, and Queen Mary University, London. My research is mainly focused on institutional change, innovation in the biopharmaceutical industry, and firms’ political (nonmarket) strategies.
Skills and Expertise
Current institution
Publications
Publications (5)
A nascent research stream on early stage disruptive innovation identified the external environment as a central mechanism that predict their success or failure. However, despite its prominence, this research stream suffers from two major weaknesses. First, it rests on an under-socialized view of the external environment which ignores the cultural a...
This paper investigates how morally contested innovations emerge and spread within an organisational field and how entrepreneurs utilize strategies to legitimize them. Building on the insight derived from a case study of the cardboard coffin's introduction in the French funeral services field our findings show that proponents of morally contested i...
Purpose
– The purpose of this paper is to enrich empirical studies on institutional entrepreneurship (IE), more specifically those focusing on the role of the IE in building a new field (here the orphan drug [OD] field). This research addresses the main paradoxes of IE theories: a deterministic vs free agent point of view; an individual hero vs a c...
This research intends to investigate the relationship between criticism of firms and individual and collective strategies they use to address and exploit it. The case study of the orphan drug field in the United States and Europe shows the ability of firms to recover criticism and develop strategic responses allowing them to seize and/or create new...
